Development of Small Molecule Drug for Stroke

• Targeted Stroke Drug Development
  • Stroke Drug Development Targeting Noncoding RNAs
  • Stroke Drug Development Targeting PSD-95
  • Stroke Drug Development Targeting Tau
  • Stroke Drug Development Targeting Heat Shock Protein 70
  • Stroke Drug Development Targeting Notch
  • Stroke Drug Development Targeting Guanosine
  • Stroke Drug Development Targeting Nogo-A
  • Stroke Drug Development Targeting Nrf2
  • Stroke Drug Development Targeting DAPK1
  • Stroke Drug Development Targeting AMPK
  • Stroke Drug Development Targeting Caveolin-1
• Stroke Drug Development Targeting Cell Death
  • Stroke Drug Development Targeting Ferroptosis
  • Stroke Drug Development Targeting Pyroptosis
  • Stroke Drug Development Targeting Necroptosis
• Stroke Drug Development Targeting Different Cell Types
  • Stroke Drug Development Targeting Astrocytes
  • Stroke Drug Development Targeting Microglia
• Stroke Drug Development Targeting Other Components
  • Stroke Drug Development Targeting Mitochondria
  • Stroke Drug Development Targeting Autophagy
  • Stroke Drug Development Targeting Epigenetic Mechanisms
  • Stroke Drug Development Targeting Blood Brain Barrier
  • Stroke Drug Development Targeting Excitotoxicity

    • Stroke Drug Development Targeting NMDAR
    • Stroke Drug Development Targeting The GluN2B Subunit of NMDAR
    • Stroke Drug Development Targeting Glutamate

While the rise of biologics has enriched the types of drugs and improved cure rates, small molecule drugs have always been an important area of drug development. Ace Therapeutics offers comprehensive services for the development of small molecule drugs for stroke therapy. We provide professional and comprehensive services for drug screening, drug efficacy testing, pharmacokinetic testing, safety evaluation testing, and pharmaceutic preparations. Our comprehensive services are designed to facilitate the smooth conduct of your research.

Targeted Stroke Drug Development

For different targets, Ace Therapeutics offers different services according to their specific mechanisms of action.

• Extensive cell banks to provide reliable and consistent quality cells
• Ultra-large small molecule libraries to allow different approaches to drug screening
• Different drug screening platforms for rapid screening of drug candidates

Stroke Drug Development Targeting Cell Death

Cell death is one of the important pathways in the elaboration of the pathological processes it undergoes, and is an important target in the regulation of stroke pathology. In view of this, Ace Therapeutics offers a comprehensive service to develop stroke drugs for different cell death types.

• Given the role of iron metabolism, lipid peroxidation metabolism, and amino acid metabolism in ferroptosis, we offer a specialized drug screening service to screen for modulators targeting these pathways with potential therapeutic effects in stroke.
• Given the role of inflammation in pyroptosis, we perform high throughput screening for inhibitors targeting inflammatory pathways associated with pyroptosis with the aim of obtaining drugs with potential therapeutic activity in stroke.
• Necroptosis is a specific type of programmed cell death. Given the important role of RIP1, RIP3, and MLKL in necroptosis, we conducted a comprehensive screening for regulators of RIP1, RIP3, and MLKL-related signaling pathways in stroke pathology with the aim of obtaining drugs with potential therapeutic activity in stroke.

Stroke Drug Development Targeting Different Cell Types

Different cell types, especially brain cells, can mimic the pathology of the post-stroke brain to some extent. At the same time, the different roles of brain cells are targeted to screen for appropriate modulators to obtain drug candidates with potential stroke therapeutic effects. With this in mind, Ace Therapeutics offers comprehensive services to develop stroke drug studies targeting different cell types. Based on different drug screening platforms, we screen different cellular synapses, receptors, or targets for active sites of action, and also perform drug screening of different sites for drug candidates with potential stroke activity.

Stroke Drug Development Targeting Other Components

Ace Therapeutics offers comprehensive services to address the role of other factors in the development of stroke drugs. With our professional equipment, advanced technology, and proven service processes, we can ensure the smooth conduct of your study.

Ace Therapeutics is a preclinical CRO biotechnology company focused on the stroke field. We have decades of research experience in the stroke field.

• We have established different methods of constructing animal models for the stroke drug development research process. Therefore, we provide you with appropriate stroke animal models for different drug development approaches.
• For drug efficacy testing, pharmacokinetic testing, safety evaluation testing, and pharmaceutic preparation, we also offer specialized services for comprehensive preclinical evaluation of drug candidates.

Our services are flexible and can be tailored to your research and needs. If you would like to learn more about our services, please feel free to contact us.